Close Menu
August 29, 2019
Sponsored by
PerkinElmer

Biobanking at Scale to Support Precision Medicine

GenomeWebinar

This webinar outlines how RUCDR Infinite Biologics, the world's largest university-based biorepository, has implemented workflows and processes to support precision medicine applications.

RUCDR Infinite Biologics, a unit of the Human Genetics Institute of New Jersey, has been perfecting the science of biobanking, bioprocessing, and analytics. In this webinar, Andrew Brooks introduces how RUCDR Infinite Biologics has created novel workflows to address precision medicine applications and presents an overview of these workflows, cutting edge analytical approaches, and robust biomaterial storage processes.  

With a focus on primary sample processing and new technological innovations allowing for efficient and cost-effective nucleic acid extraction, he describes how discovery processes are maximized, and precious biomaterial resources are protected for future analyses in both research and clinical applications.

Sponsored by

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.

Feb
27
Sponsored by
Stilla

Since the publication of the “The Digital MIQE Guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments” (dMIQE) in 2013, there has been a large expansion of the applications of dPCR such as single nucleotide variations (SNVs) and copy number variations (CNVs) measurements associated with disease diagnostics.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.